fezakinumab

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 457119778

| type = mab

| image =

| alt =

| mab_type = mab

| source =

| target = IL-22

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1007106-86-6

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 0S77U25XZ3

| PubChem =

| KEGG = D09615

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C=6408 | H=9873 | N=1706 | O=2016 | S=44

}}

Fezakinumab is a human monoclonal antibody against interleukin-22,{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/fezakinumab.pdf|access-date=2017-06-07}} designed for the treatment of psoriasis and rheumatoid arthritis.{{cite web |url=http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf |title= Pfizer Pipeline | date = 28 February 2011 |access-date=2012-09-25 |url-status=dead |archive-url=https://web.archive.org/web/20110904221453/http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf |archive-date=2011-09-04 }}

Research and development

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,{{cite web|url=http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4 | archive-url = https://web.archive.org/web/20180124135800/http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4 | archive-date = 24 January 2018 |title = Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis | work = Living Medical eTextbook - Rheumatology - Projects In Knowledge |page=4| access-date=2017-06-07}} but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.{{cite web|vauthors=Richardson B|title=Atopic dermatitis: fezakinumab shows benefit in severe disease|url=http://quantiamd.univadis.com/player/yfprpshwk?u=bhabzahbt|website=quantiamd.univadis.com|publisher=Aptus Health|access-date=24 January 2018|archive-date=25 January 2018|archive-url=https://web.archive.org/web/20180125015425/https://quantiamd.univadis.com/player/yfprpshwk?u=bhabzahbt|url-status=dead}}

References

Category:Drugs developed by Wyeth

Category:Drugs developed by Pfizer

Category:Abandoned drugs